Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.
The abstract ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.’ (Abstract number LBA1) was presented at the ASCO annual meeting, 3-7 June 2022.
Questions
- What were the aims, design and eligibility criteria of the PARADIGM trial? (00:14-01:36)
- What was the primary endpoint and how well was it achieved? (01:36-02:50)
- What will be the impact of these findings on clinical practice? (02:50-03:38)
Disclosures: Takayuki Yoshino has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
